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A B S T R A C T
The durability of prosthetic arteriovenous (AV) grafts for hemodialysis access is low, predominantly due to stenotic lesions in the venous outflow tract and infectious
complications. Tissue engineered blood vessels (TEBVs) might offer a tailor-made autologous alternative for prosthetic grafts. We have designed a method in which
TEBVs are grown in vivo, by utilizing the foreign body response to subcutaneously implanted polymeric rods in goats, resulting in the formation of an autologous
fibrocellular tissue capsule (TC). One month after implantation, the polymeric rod is extracted, whereupon TCs (length 6 cm, diameter 6.8 mm) were grafted as
arteriovenous conduit between the carotid artery and jugular vein of the same goats. At time of grafting, the TCs were shown to have sufficient mechanical strength in
terms of bursting pressure (2382 ± 129mmHg), and suture retention strength (SRS: 1.97 ± 0.49 N). The AV grafts were harvested at 1 or 2 months after grafting.
In an ex vivo whole blood perfusion system, the lumen of the vascular grafts was shown to be less thrombogenic compared to the initial TCs and ePTFE grafts. At 8
weeks after grafting, the entire graft was covered with an endothelial layer and abundant elastin expression was present throughout the graft. Patency at 1 and 2
months was comparable with ePTFE AV-grafts. In conclusion, we demonstrate the remodeling capacity of cellularized in vivo engineered TEBVs, and their potential as
autologous alternative for prosthetic vascular grafts.
1. Statement of significance
Tissue engineered blood vessels are considered a promising alter-
native for prosthetic vascular grafts as arteriovenous vascular access for
hemodialysis. In a goat model of arteriovenous grafting, we have de-
monstrated sufficient mechanical characteristics of in situ engineered
vascular grafts to allow safe vascular grafting with similar patency rates
compared to ePTFE AV-grafts. This indicates that in situ TEBVs are a
robust vascular graft, with the potential to be used in as arteriovenous
vascular access for hemodialysis.
2. Introduction
The high failure rate of vascular access sites contributes to the rising
cost of renal replacement therapy [1,2], a growing issue when com-
bined with the increasing prevalence of end-stage renal disease [3].
Autologous vessels offer the best patency rates with regard to vascular
grafting. However, preexisting disease, previous harvesting, and un-
suitability for a vascular procedures limits their use [4]. Synthetic op-
tions however, are prone to infection, intimal hyperplasia (IH), and/or
thrombosis [5,6]. Thus, tailor-made tissue-engineered blood vessels
(TEBVs) may serve as a viable alternative to synthetic grafts.
A wide range of tissue-engineering approaches have been suggested
for replacing synthetic grafts [7]. One such method involves the so-
called mandril-based approach, which relies on the foreign body re-
sponse (FBR) driving the development of an autologous in vivo cellu-
larized vascular substitute surrounding an implanted medical device
[8]. Using both in vivo [9,10] and in vitro [11] approaches, we pre-
viously reported that the implant's surface characteristics can influence
the resulting FBR, thereby affecting the composition of the tissue that
forms around the implant. Based on these studies, we found that sub-
cutaneously implanted polymeric rods can elicit an FBR, resulting in the
encapsulation of the rods with a fibrocellular tissue capsule that can
then be grafted into the vasculature as a carotid interposition, enabling
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remodeling of the tissue into a vascular phenotype [9]. Moreover, our
group has recently demonstrated that the presence of uremia does not
impact the formation of the tissue capsules in vivo [12].
Here, we report the generation of functional TEBVs using a goat
model of vascular grafting, and we describe the dynamic properties by
which grafted TEBVs remodel to produce a suitable vascular phenotype.
The arteriovenous grafting model was chosen as it allows the functional
assessment of TEBVs in terms of vascular remodeling and patency in a
rigorous setting.
3. Methods
3.1. Study design
All experiments were approved by the Animal Care and Use
Committee of the University Medical Center Utrecht and were per-
formed in accordance with Dutch and European legislation. The study
included 17 adult female Dutch milk goats that were randomly divided
into a TEBV group (n= 8) and an ePTFE control group (n= 9). Each
animal received nadroparin (15,000 IU SID) starting the day after
vascular grafting and clopidogrel (150mg SID) after a loading dose of
300mg beginning 7 days prior to grafting and continuing until the
animal was sacrificed. One day prior to surgery, the goats received a
buprenorphine patch (5 μg/h delivery rate) and were fasted overnight.
For the TEBV group, two cylindrical-shaped polymer rods were im-
planted subcutaneously in the neck. The neck was chosen as an im-
plantation site as this allowed good surgical access to the carotid artery
and jugular vein, from which an arteriovenous conduit could be
grafted. In addition, implantation in the neck provided the option to
check patency of the arteriovenous graft manually. One month later,
the rods with tissue capsules grown around them were harvested, and
one tissue capsule was grafted as an arteriovenous conduit between the
carotid artery and jugular vein in the same goat. The cylindrical shaped
tissue that forms around the implant is considered a tissue capsule,
while it is considered a TEBV as soon as it is grafted into the vascu-
lature. The other tissue capsule was used for histology, mechanical
testing, thrombogenicity assays, and cell culture experiments. In three
animals, an additional rod was implanted during the grafting operation
to ensure that one month after grafting a TEBV, TC, and artery could be
harvested for use in the thrombogenicity assay (see Fig. 1).
Patency of the graft was monitored weekly using ultrasonography
with a CX50 ultrasound machine (Philips, Eindhoven, the Netherlands).
One and two months after grafting, 5 and 3 animals, respectively, were
euthanized and the grafts were removed for histological analysis,
thrombogenicity assays, and cell culture experiments. Pre-grafted tissue
capsules were compared to post-grafted tissue capsules for their ability
to remodel within the vasculature. In contrast, the control group re-
ceived a 6-mm ePTFE graft placed between the carotid artery and ju-
gular vein; this graft was left in place for one or two months (n= 6 and
n=3, respectively), after which the animals were euthanized and the
grafts were removed for histological analysis and thrombogenicity as-
says.
3.2. Production of polymer rods
Cylindrical solid rods (6 mm in diameter and 6 cm in length) were
fabricated using a specially designed mold at the MERLN Institute for
Technology-Inspired Regenerative Medicine, Maastricht, the
Netherlands. The rods were composed of the co-polymer poly(ethylene
oxide terephthalate)–poly (butylene terephthalate) (PEOT/PBT;
PolyVation, Groningen, the Netherlands) with a weight ratio of PEOT/
PBT of 55/45 and an initial molecular weight of 300 g/mol. In brief,
polymer pellets were heated to 165 °C, injected into the mold, and al-
lowed to gradually cool before removing the rods. The rods were then
cleaned with 70% ethanol, the tips were rounded in order to facilitate
implantation, and the surface of the rods was modified as described
previously [9,10]. The rods were briefly submerged in chloroform,
washed, and then dried under nitrogen gas. The surface topography of
the rods was confirmed using SEM analysis. The rods could not be
broken with the application of manual pressure. Due to a single faulty
polymer batch, rod breaking was an issue in a subset of implants, these
rods were excluded from the analysis performed here.
3.3. Surgical procedures
Two polymeric rods were implanted in the neck of each goat by
making a small incision and bluntly preparing a subcutaneous pocket
approximately 9 cm in length. For the animals used in the thrombo-
genicity assay (n= 3), an additional rod was implanted during the
vascular grafting surgery. Each rod was secured to the surrounding
subcutaneous tissue using 2-0 Prolene sutures at both ends. One month
after implantation, the neck was opened via a midline incision and the
polymer rods—including the surrounding tissue capsules—were re-
moved by gentle dissection, after which the rod was extruded easily
from the tissue. The integrity of the tissue capsule was confirmed by
inflation with saline, and the tissue capsule was then implanted as an
end-to-side arteriovenous conduit between the carotid artery and the
jugular vein using running 6-0 Prolene sutures. Flow was measured at
the time of grafting and at termination using a perivascular probe. In a
subset of animals, an angiogram was performed using a Allura Xper
FD20 angiograph (Phillips) in order to confirm post-surgical positioning
of the TEBV.
3.4. Mechanical testing of tissue capsules
All mechanical tests were performed in accordance with ISO-7198-
1998 guidelines [13]. To measure suture retention strength, a suture
was placed at three locations at a depth of 2mm in the tissue using 5-0
Vicryl (Ethicon, Johnson & Johnson) and pulled at a steady rate of
5.0 mm/min; the maximum force applied was recorded using a Kern
5K5N hanging scale (Kern, Balingen, Germany) with a resolution of
0.05 N. Prior to grafting, dynamic compliance was measured for a tissue
capsule 6 cm in length, which was strained with a load of 0.5 N and
placed in a specially designed compliance measurement system at
37 ± 1 °C; the sample was then subjected to a pulsatile pressure of
120/80mmHg at 1 Hz. Pulsations were recorded using a high-definition
microscope camera with an accuracy of± 0.02mm, while simulta-
neously using a TruWave pressure transducer (Edwards Lifesciences,
Irvine, CA) and a model 700G pressure gauge (Fluke, Eindhoven, the
Netherlands). The temperature was recorded using a model PCE-779 N
infrared thermometer (PCE instruments, Enschede, The Netherlands).
Compliance of each vessel was determined by combining the high-de-
finition images with the corresponding pressure data. To determine the
vessel's bursting pressure, a 5-cm tissue capsule was perfused with
saline at 37 ± 1 °C with steadily increasing pressure until the graft
ruptured (Suppl. Video S1). Methylene blue was added to the saline
solution in order to accurately determine the burst location and to
confirm that the rupture did not occur at the vessel connectors. All
ruptures occurred away from the connectors.
Supplementary data related to this article can be found at https://
doi.org/10.1016/j.biomaterials.2019.119577.
3.5. Sample preparation and histology
For histology and immunohistochemistry, tissues were fixed in 4%
formaldehyde, processed, and embedded in paraffin. Cross-sections
(5 μm thickness) were cut from the tissue capsule before grafting, 1
month after grafting, and 2 months after grafting; these sections were
used for thrombogenicity assays. Picrosirius red‒stained sections were
analyzed for the presence of collagen. A hematoxylin phloxine saffron
(HPS) stain was used to assess cellular alignment. To examine cellular
composition, immunohistochemistry was performed using the
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following antibodies: α-smooth muscle actin (α–SMA, Dako,
Amstelveen, the Netherlands; 1:1000) for myofibroblasts; vimentin
(Immunologic, Duiven, the Netherlands; 1:100) for fibroblasts; desmin
(Immunologic; 1:100), myosin (smooth muscle) heavy chain (Alfa
Aesar, Karlsruhe, Germany; 1:200) for contractile vascular smooth
muscle cells (VSMCs); Calprotectin (Bio-Rad, Munich, Germany; 1:100)
for macrophages; and eNOS (BD, Vianen, the Netherlands; 1:2500), and
Elastin (Sigma-Aldrich, Houten, the Netherlands; 1:2500) for en-
dothelial cells. Each antibody was visualized using 3,3′-diamino-
benzadine (DAB), and the sections were counterstained with hema-
toxylin. Where necessary, antigen retrieval was performed using heat-
induced 0.1% trypsin. Fluorescence and bright-field images of the
stained sections were obtained using a panoramic slide scanner
(3DHistec, Budapest, Hungary). All stained sections were compared to
their respective isotype controls and control tissues. To quantify the
staining, the percentage of DAB positivity relative to the total area (for
fibroblasts, myofibroblasts, and smooth muscle cells) was quantified
using ImageJ software with three histological sections per sample. For
each sample, a minimum of three histological sections (HPS staining)
near the venous anastomosis were used to assess stenosis, in which the
lumen surface area was compared (as a percentage) to the area of the
original lumen.
3.6. Contractility assay
Primary VSMCs from a carotid artery, VSMC-like cells from a TEBV,
and fibroblasts/myofibroblasts from a tissue capsule were isolated from
two animals. If present, the endothelial monolayer was detached by
gently scraping with sterile surgical forceps. Care was taken to ensure
that the tissue from the tunica media of the artery and the luminal
tissues of the TEBV and tissue capsule were isolated. The samples were
dissected into small pieces and plated on 60-cm Petri dishes pre-coated
with collagen (Purecol, 10 μg/ml). After 14 days in culture with
DMEM/F12 medium supplemented with 10% fetal calf serum (FCS),
100 U/ml penicillin, and 100 μg/ml streptomycin, the cells were tryp-
sinized and re-plated on 10-cm Petri dishes and cultured for an addi-
tional 7 days. At approximately 80% confluence, the cells were tryp-
sinized and used for the contractility assay. The HFF1 cell line was used
as a control and was cultured in DMEM supplemented with 10% FCS,
100 U/ml penicillin, and 100 μg/ml streptomycin. For each sample,
20,000 cells were plated in triplicate on silicone elastomer dishes con-
taining DMEM/F12 medium supplemented with 1% FCS, 100 U/ml
Fig. 1. Schematic overview of the experimental
setup used for the thrombogenicity assay performed
on explanted samples. A) In 3 animals, an additional
rod was implanted during the grafting surgery
(t= 0); at t= 1 month a TEBV, TC, and artery were
harvested from a single animal. A sterile new piece of
ePTFE was used as a control. The vessel samples
were cut open and placed longitudinally in a sample
holder chip with the sample's lumen exposed. The
samples were immersed in HEPES buffer at all times
during handling. B) The sample holders were placed
in parallel in a specially designed ex vivo perfusion
chambers. Blood from a second animal was perfused
in parallel over the ROI in the chamber at a rate of
12.5 ml/min, with blood being drawn from the an-
imal into and into the syringes. After a total volume
of 6.25ml had perfused over the chamber, 37 °C
HEPES was automatically perfused over the samples
at 12.5 ml/min to wash the samples. C) Left: Image
of tracer particles flowing through the chamber for
particle image velocimetry. Right: Pseudocolor
image showing the velocity fields generated by the
samples; note that the flow is homogeneous at the
ROI.
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penicillin and 100 μg/ml streptomycin. Deformable silicone elastomer
(5 kPa) 24×24 mm Petri dishes were coated overnight with collagen
in serum-free DMEM/F12 prior to use. Twenty-four hours after the cells
were plated, bright-field microscopy images were taken of ten random
fields of view at 100× magnification. Sample contractility was de-
termined by counting the number of contractile cells per field of view
and is expressed relative to the total number of cells, as described
previously [14]. Cell contractility was determined by the presence of
visible deformations in the elastomer beneath the cells.
3.7. Thrombogenicity assay
One month after grafting, the animal was sacrificed and a 2-cm mid-
graft section of the TEBV, the un-operated contralateral carotid artery,
and an ungrafted tissue capsule were removed (n=3). Using great
care, the samples were directly placed in 37 °C HEPES buffer, and the
tissue rings were cut open and placed into sample holders. Care was
taken to ensure that the samples were not directly exposed to air. The
sample holders were placed in a specially designed ex vivo perfusion
chamber (Fig. 1A). A sterile new piece of ePTFE was used as a control.
Blood was drawn from the jugular vein of a control animal that had
received no therapeutics and was perfused at a rate of 12.5 ml/min over
all samples in parallel using a syringe pump with a total volume of
6.25ml (Fig. 1B). The flow system was designed to ensure that all
samples received exactly the same volume of blood and flow rate.
Moreover, this flow rate allowed a stable shear rate of 20 dyn/cm2 to be
attained in all chambers. After 30 s of perfusion, the samples were
washed with 37 °C HEPES buffer. The flow chamber was then opened,
and each sample was divided into two sections. One section was washed
in 37 °C HEPES and fixed in 1% paraformaldehyde for confocal mi-
croscopy. The other section was washed in 37 °C HEPES and fixed in
glutaraldehyde for 2 days for SEM analysis. To examine luminal ad-
hesiveness, SEM imaging was performed using an ROI in which the flow
rate and shear stress were stable between samples based on our char-
acterization experiments (Fig. 1C); thus, the same imaging location was
used for all samples.
To investigate the flow characteristics of the ex vivo flow chamber,
particle imagevelocimetry (PIV) was performed in separate experiments
[15]. These measurements were performed using an ex vivo flow
chamber that contained an ePTFE graft in the sample holder. A water-
glycerol solution (with a density of 1100 kg/m3 to mimic the viscosity
of whole blood) was perfused at 37° though the system to generate
pressure-driven flow with a constant flow rate of 12.5ml/min using a
neMESYS pump (Cetoni, Korbussen, Germany). The solution was
seeded with monodispersed polyethylene microspheres (106–125 μm
diameter; Cospheric, Santa Barbara, CA). Images were recorded using a
LaVision Imager sCMOS camera (sCMOS, 16-bit, 2560×2160 pixels,
pixel pitch 6.5 μm). Image acquisition and PIV processing were per-
formed using LaVision DaVis version 8.3 to create a flow field derived
from the setup (Fig. 1C).
3.8. Statistical analysis
All summary data are presented as the mean ± the standard error
of the mean. Data for the mechanical tests were analyzed using the
Mann-Whitney U test using GraphPad Prism version 7.00. Differences
with a P-value< 0.05 were considered statistically significant.
4. Results
4.1. Formation of the TEBVs
The surface properties of the implanted rods were analyzed using
scanning electron microscopy (SEM). Gamma irradiation did not affect
the surface topography of the rods (data not shown). One month after
implantation, a thick tissue capsule had formed around each implanted
rod (Fig. 2A). This tissue capsule was easily removed from the rod, was
easy to handle for surgical procedures, and was suitable for use in
forming an arteriovenous conduit (Fig. 2B).
4.2. Mechanical properties of the TEBVs
The burst pressure, suture retention strength, and dynamic com-
pliance of the TEBVs are summarized in Fig. S1. The burst pressure was
2382 ± 129mmHg; although this is lower than the burst pressure of a
native human artery, it is higher than the burst pressure of a native
human vein and far exceeds physiological blood pressure levels [16].
The suture retention strength of our TEBVs was 1.97 ± 0.49 N, with
little variance between samples; this strength exceeds the requirements
for safe grafting, which are generally defined by the mechanical prop-
erties of the saphenous vein [7,16].
4.3. Tissue capsule formation and remodeling to form a vascular phenotype
Prior to grafting, the tissue capsule is composed of extracellular
matrix components (Fig. 3), fibroblasts, and myofibroblasts (Fig. 4A–C),
with several macrophages lining the inner layer (Fig. 3C). Collagen is
also abundant in the TC, as shown using picrosirius red staining
(Fig. 3D). In contrast, the tissue capsule does not contain elastin
(Fig. 3A) or an endothelial lining (Fig. 3B) prior to grafting. The eNOS-
positive cells in the pre-grafted tissue capsule are attributed primarily
to capillaries, confirming that the tissue capsule is well-vascularized
(Fig. 3). Extremely few foreign body giant cells were observed; how-
ever, the presence of calprotectin-positive cells (Fig. 3C) indicates the
presence of macrophages in the luminal region. The majority of cells
present in the tissue capsule are vimentin-positive, α-SMA‒positive,
desmin-positive fibroblasts and myofibroblasts (Fig. 4A–C); however, at
this stage the cells lack the features of contractile smooth muscle cells
(e.g., they do not express myosin heavy chain (HC)) (Fig. 4D).
After grafting, the tissue capsule underwent remodeling, forming a
thick-walled graft. One month after grafting, the majority of cells in the
inner lining of the TEBV were vimentin-positive, α-SMA‒positive, and
Fig. 2. A) Example image of a tissue capsule grown around an implanted rod prior to grafting. B) A tissue capsule implanted as an arteriovenous conduit to form a
TEBV. C) Example angiogram used to assess the position of the TEBV.
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Fig. 3. Mid-graft cross-sections showing a notable increase in elastin expression (A), a clearly defined endothelial monolayer (B), an absence of inflammatory cells
two months after grafting (C), and an abundance of collagen (D).
Fig. 4. Immunohistochemistry showing the cellular composition of native arteries, tissue capsules, TEBVs at 1 month, and TEBVs at 2 months.
W.J. Geelhoed, et al. Biomaterials 229 (2020) 119577
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desmin-positive (Fig. 4A–D), consistent with smooth muscle cell-like
properties; interestingly, however, some of the cells were also myosin-
HC‒positive. Two months after grafting, nearly all of the cells in the
inner lining of the graft were strongly myosin-HC‒positive (Fig. 4D).
Moreover, at 1 month, the tissue capsules lacked elastin; in contrast, the
tissue capsule expressed high levels of elastin 2 months after grafting
(Fig. 3). Of note, the distribution of elastin varied throughout the vessel
(Fig. S2), consistent with the putative contribution of elastin formation
to the TEBV's hemodynamic properties. In addition, the VSMC (vascular
smooth muscle cell)-like cells are circumferentially aligned (Fig. S3B),
closely mimicking the morphology of mature arterial cells (Fig. S3C).
One month after grafting, isolated and cultured luminal cells have a
notable increase in contractility compared to cells isolated prior to
grafting (Fig. 5A–B). This finding supports the histologically identified
contractile phenotype.
4.4. Thrombogenicity assay and characterization of the ex vivo whole blood
perfusion chamber
Next, we performed an ex vivo thrombogenicity assay in order to
determine whether the endothelium present in the TEBVs (see Fig. 3)
confers anti-thrombotic properties to the vessel's surface. The perfusion
chambers used in the assay were capable of perfusing four samples in
parallel, with a constant flow rate and equal blood volume (Fig. 1B),
while using a small (10mm×5mm) patch of tissue. The tissue samples
exposed to whole blood flow were then compared to separate samples
that were not perfused.
We then examined the flow characteristics of the ex vivo flow
chamber using particle image velocimetry (PIV) and found that the flow
was stable in the region of interest (ROI) with minimal fluctuations in
flow velocity. The mean velocity in the ROI was 2mm/s, and the cor-
responding Reynolds number was 0.733; thus, the flow is laminar,
steady, and reproducible. We used a standardized flow rate of 12.5 ml/
min in the system, generating an average wall shear stress in the ROI of
1.44 N/m2 (14.4 dyn/cm2); this is comparable to the time-averaged
arterial shear stress levels (Fig. 1C). SEM analysis revealed that ex vivo
perfusion of our samples caused a notable decrease in the adhesive
capacity of the tissue capsule's luminal surface after it had been grafted
and exposed to the circulation for one month, as compared to the non-
grafted tissue capsules which had not been exposed to the circulation.
Exposing pre-grafted tissue capsules to non-anticoagulated whole blood
drawn directly from the jugular vein of a goat caused the complete
coverage of the tissue with thrombocytes and fibrin; no adhesion of
fibrin and thrombocytes occurred when exposing carotid artery samples
to exposed to blood (Fig. 6A). In contrast, no blood components ad-
hered to TEBVs obtained 1 month after vascular grafting (Fig. 6A–B),
confirming that the eNOS-positive endothelial lining on the TEBV's
luminal surface is functional (Fig. S5). Importantly, two ePTFE samples
did not have adherence, although a protein/fibrin-rich structure ad-
hered to a third ePTFE sample (Fig. 6A and C3). Our analysis revealed
that primarily erythrocytes were present in the artery sample (Fig. 6C1).
4.5. Patency of TEBV grafts and ePTFE grafts
Lastly, we compared patency between our TEBV grafts and synthetic
ePTFE grafts; the results are summarized in Table 1. One month after
vascular grafting, 4 of the 5 TEBV grafts and 5 of the 6 ePTFE grafts
remained patent; two months after grafting, 2 out of 3 TEBV grafts and
1 out of 3 ePTFE grafts were still patent. At 1 month, stenosis in the
non-occluded (i.e., patent) TEBV grafts was higher than in the non-
occluded ePTFE grafts (52.22 ± 29.10% versus 4.17 ± 1.95%, re-
spectively); in contrast, at 2 months stenosis in the TEBV grafts was
lower than in the ePTFE grafts (12.94 ± 16.19% versus 85.61%, re-
spectively) (Table 1). The stenoses in both the TEBV and ePTFE grafts
formed primarily near the venous anastomosis, and in the venous
outflow tract. The majority of cells in the stenotic lesions near the ve-
nous anastomosis were vimentin- and α-SMA‒positive fibroblasts and
calprotectin-positive macrophages (Fig. 7 and Fig. S6). Moreover, none
of the TEBV or ePTFE grafts developed calcification (Fig. S7).
5. Discussion
Here, we report that engineered TEBVs can be generated by in vivo
remodeling of autologous fibrocellular tissue capsules. Notably, our
TEBVs have low thrombogenicity and is composed of cells with a
functional contractile phenotype. Moreover, the pre-grafted tissue
capsules exhibit sufficient mechanical properties to restrain arterial
pressure. At this stage, the tissue capsules are composed primarily of
fibrocellular tissue with very little elastin; therefore, the dynamic
compliance of the tissue capsules is lower than that of a native artery.
Importantly, the patency rate was similar between TEBV grafts and
synthetic ePTFE grafts both one and two months after vascular grafting.
Growing the tissue capsule within the subcutaneous space over a 1-
month period facilitated the growth of an autologous, cellularized TEBV
that has sufficient mechanical strength and can be successfully grafted
into the vasculature. In a previous study we have already demonstrated
the capacity of the TEBV to be successful cannulated, with a time to
hemostasis of only 3min [9]. Moreover, these TEBV can remodel to
form a vascular phenotype with VSMC-like properties and a functional
endothelial layer, which were confirmed using histology and a novel
thrombogenicity assay.
Prior to vascular grafting, the tissue capsules were composed pri-
marily of fibroblasts, myofibroblasts, and collagen. Fibroblasts are
characterized by remarkable plasticity [17–19], with the ability to
Fig. 5. A) Bright-field images of the cells used in the contractility assay. B) Quantification of contractile cells isolated from two arteries, two tissue capsules (TC), and
two TEBVs showing an increase in contractility between the tissue capsules and TEBVs measured 1 month after grafting. The HFF1 cell line was used as a control.
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differentiate into VSMCs [20]. Even though the initial tissue capsule
was composed almost entirely of fibroblasts and numerous luminal
macrophages, within a month of vascular grafting the tissue capsules
began to show a notable increase in desmin-positive VSMC-like cells, as
well as a notable decrease in macrophages. Two months after grafting,
the number of myosin-HC‒positive cells had increased further, and a
clearly defined endothelial lining with confirmed anti-thrombogenic
properties was present. Importantly, virtually no macrophages were
observed at this stage. Based on functionality, protein expression, and
the cell types present, the densely cellularized nature of the tissue
capsule clearly resulted in the capsule's differentiation into a vascular
phenotype upon exposure to hemodynamic factors. Whether the VSMC-
like cells originated from infiltrating cells or differentiated from
Fig. 6. A) Example SEM images of the indicated tissues before (left column) and after (right column) laminar whole blood perfusion at arterial shear. After perfusion,
the arterial sample contains only erythrocytes gathered in the folds of the artery. The perfused tissue capsule sample is completely covered in shear-aligned fibrin
fibers with numerous erythrocytes and some thrombocytes. The TEBV sample has only minor adhesion of compounds. Finally, the ePTFE sample has extremely little
adhesion of compounds. B) Quantification of adhesion before and after flow. Note the drastic decrease in the adhesive capacity of the TEBV one month after grafting.
C) Detailed images of adherent structures (arrows) observed after the various tissues were perfused. C1: The arterial tissue has erythrocytes adhered to it. C2: Example
ePTFE covered with fibrin fibers that were possibly degraded by fibrinolytic enzymes. C3: Example of an ePTFE sample containing non-descript adherent structures.
C4: A tissue capsule sample showing shear-aligned fibrin structures that have captured red blood cells. C5: Example TEBV showing adherent non-erythrocyte cells,
which were possibly monocytes or endothelial progenitor cells. C6: A tissue capsule sample with attached thrombocytes.
Table 1
Summary of the patency and stenosis rates of TEBVs and ePTFE grafts harvested
one or two months after grafting.
Number of
grafts
Patent % Stenosisa (mean ± Standard error
of the mean)
TEBV 1 month 5 4 52.2 ± 14.6
TEBV 2 months 3 2 12.9 ± 11.5
ePTFE 1 month 6 4 4.2 ± 1.2
ePTFE 2 months 3 1 85.6
a Only the patent grafts were included in this analysis. SEM, standard error of
the mean.
Fig. 7. Example cross-sections of stenotic lesions in a TEBV and ePTFE obtained one month after grafting, with immunohistochemistry to stain various cell types
present in the lesion. Overall, the cellular composition was similar between the two lesions.
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fibroblasts/myofibroblasts present in the tissue capsule is currently
unclear. Similarly, the origin of the endothelial cells is unclear, as they
may have been derived from endothelial progenitor cells (EPCs) [21] or
via ingrowth from the artery and/or vein [22]. Pre-seeding the luminal
surface of a vascular graft with endothelial cells is both labor-intensive
and costly and requires access to a well-equipped facility [23]. In this
respect, an autologous, cellularized graft can be reendothelialized more
easily, thereby providing long-term patency. Moreover, our finding that
the cells are distributed uniformly two months after grafting indicates a
morphological shift from the initial cells in the tissue capsule to VSMC-
like cells. Finally, we found no signs of calcification in either the TEBV
or ePTFE grafts.
In native blood vessels, the vascular endothelium plays an essential
role in preventing the formation of intimal hyperplasia (IH), throm-
bosis, and calcification [23]. At the time of vascular grafting, the tissue
capsules lacked an endothelial lining of the luminal surface. However,
because the surface of the tissue capsule is rich in collagen, tissue fac-
tors, and ECM components, it is intrinsically thrombogenic material.
Using a pig model of arterial interposition grafting, we previously re-
ported that the tissue capsule becomes endothelialized following vas-
cular grafting [9]. Using a parallel ex vivo flow experiment under
controlled standardized circumstances, we now report that the TEBV
has reduced adhesive properties after vascular grafting compared to the
initial, pre-grafted tissue capsule. This change may be attributed to the
formation of an endothelial layer monolayer that closely mimics a na-
tive artery within two months of grafting.
Compelling evidence suggests that both fibrin and platelets are es-
sential for the endothelialization that occurs in our model. After ex-
posure to whole blood, a structure formed that was based on the di-
rection of flow and consisted of aligned fibrin, erythrocytes, and
platelets. Importantly, this process did not result in acute thrombus
formation in the grafted TEBVs, despite starting low molecular-weight
heparin (LMWH) therapy only the day after surgery. The animals had
however received clopidogrel prior to surgery. This indicates the pos-
sibility that the thrombogenic response of the tissue capsule's surface
may be stabilized in an acute setting. Using a model of vascular injury,
fibrin and platelets were found to play an essential role in recruiting
endothelial progenitor cells (EPCs) and promoting their differentiation
into mature endothelial cells [24,25]. Thus, the initial thrombogenic
layer observed in the tissue capsules may be essential for either pro-
moting the future endothelialization of the lumen and/or recruiting
circulating cells to the TEBV [13].
Despite having similar patency, venous stenosis remained an issue
in both TEBV and ePTFE grafts. In both groups, the stenotic lesions
occurred either near the venous anastomosis or directly at the venous
outflow tract. Moreover, the lesions in both groups contained randomly
aligned fibroblasts, myofibroblasts, VSMC-like cells, and macrophages,
all of which are characteristic of IH [26]. A decrease in the stenotic
lesion in the TEBV at the 2-month time point compared to the 1-month
time point was observed. This decrease in stenotic lesion area is not
completely understood however it may be due to the progressive re-
modeling of the tissue over time. In the context of an arteriovenous
fistula, wall shear stress increases considerably; when combined with
turbulent flow, this can cause damage to endothelial cells and initiate
the formation of IH [27–29]. Wall shear stress is an important factor in
the development of IH [30–32]; therefore, the presence of a functional
endothelium may reduce the risk of IH.
In addition to compliance mismatch [33] and turbulent flow
[28,34–36], the inflammatory foreign body response caused by ePTFE
is considered a contributing factor to graft failure [37,38]. On the other
hand, removal of possible foreign body inflammatory factors—as in our
TEBV method—does not entirely eliminate IH, underscoring the greater
importance that compliance and hemodynamic factors play in graft
occlusion compared to inflammation, at least in the setting of vascular
access for hemodialysis. Thus, innovative new strategies to modulate
flow and/or turbulence at the vascular access site, as well as anti-
proliferative strategies, may help improve the long-term durability of
the graft.
A possible limitation of using goats as a model is their tendency for
relatively rapid stenosis formation and graft occlusion. Furthermore,
the high degree of inter-individual variation among goats and sheep
with respect to thrombogenicity [39] underscores the importance of
directly comparing patency with an ePTFE-based vascular graft or other
relevant control. The variable degree of thrombogenicity of the vascu-
lature, as well as the lack of response to acetylsalicylic acid, was a
reason that LMWH was administered to the animals, providing addi-
tional evidence of the dissimilarity between patients and conventional
animal models with respect to the vasculature. In contrast, both dogs
and baboons are less prone to developing IH [40]. Therefore, the
characteristics of the animal model, the study outcomes, and the cor-
responding control group must be taken into consideration when at-
tempting to translate the results to the broader research field. More-
over, although no chronic kidney failure was induced in this study, we
have recently reported that the presence of uremia does not impact the
formation of the tissue capsules [12].
In the late 1960s, Sparks published the first attempt to use an au-
tologous FBR-based tissue graft grown around a Dacron mesh substrate
[41]. However, incomplete understanding of the FBR, together with the
incorporation of foreign body materials into the engineered tissue, led
to the occurrence of graft rupture and aneurysm formation [42]. Later,
Campbell further developed this concept by using the peritoneal cavity
as the in vivo bioreactor [43]. As the knowledge regarding modulation
of the FBR increased, this so-called mandril-based method has been
fine-tuned and strengthened [8].
The advantage of the approach used in our study compared to other
tissue-engineering techniques is that autologous cellularized tissue is
generated entirely in vivo, without the need for expensive and time-
consuming in vitro steps, the need for host cell invasion of decellularized
scaffolds, or patient variability with respect to replacement of a de-
gradable scaffold. We show that our autologous TEBVs can undergo
remodeling within the vasculature, resulting in endothelialization and
the production of VSMC-like cells. Moreover, our method does not re-
quire a maturation period, as the TEBVs can be implanted with pre-
determined dimensions tailor-made to the needs of the individual pa-
tient. Despite its promise, the patient's age [44], gender [45], and
health status [46] can affect the FBR, and these factors must be taken
into consideration when investigating the clinical relevance of this
technique.
Based on these results, a clinical trial is currently being initiated to
examine the functionality of in vivo engineered TEBVs as arteriovenous
grafts in hemodialysis patients. Initially, tissue capsule formation in
dialysis patients will be evaluated to determine if safe grafting can be
performed. If the tissue is indeed deemed safe for vascular grafting, the
tissue capsules will be grafted as arteriovenous conduit for hemodialysis
vascular access.
In conclusion, our results provide compelling evidence that our in
vivo engineered TEBVs can be implemented as arteriovenous vascular
access. Using a robust ex vivo perfusion model, we confirmed that the
newly formed endothelium is non-thrombogenic. Moreover, we show
that our TEBVs undergo cellular reorganization to produce a vascular
morphology with elastin formation, and we show that the cells differ-
entiate into a VSMC-like phenotype. Despite the presence of stenosis in
the TEBV grafts, the patency rate was similar to ePTFE grafts, indicating
that our in vivo engineered TEBVs may serve as a viable arteriovenous
conduit, or arterial bypass grafts.
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